Date posted: 30-Oct-2013
Category: Press Releases
NovaBiotics Ltd, the clinical-stage biotechnology company, today announced that it has partnered with the Cystic Fibrosis Trust and Health Sciences Scotland, for a Phase1/2a clinical trial of its novel compound, Lynovex®.
Lynovex is being developed as a treatment for persistent lung infection in cystic fibrosis (CF). The product works by breaking down excessive mucus and killing the bacteria responsible for recurring infections. It also prevents pathogens establishing long-term, antibiotic resistant infections which are common to people living with CF.
Although in its early stages of development, Lynovex is a drug already approved for oral delivery in an unrelated orphan metabolic disease and has been shown to be safe and well tolerated so has the potential for fast-track clinical development. It has designated orphan drug status in Europe.
Cystic Fibrosis Trust’s support, NovaBiotics is also working in partnership with NHS Grampian and the University of Aberdeen’s CF research team who will undertake initial clinical evaluation and trials of Lynovex.
Deborah O’Neil, CEO of Novabiotics said:
“CF is a life-shortening respiratory disease where the treatments available require a complete re-think. Current options for patients are limited and focus primarily on either the recurrent infections or the over-production of mucus. We believe, with Lynovex, we have a much-needed solution for patients that tackle both of these issues.
“Having the Cystic Fibrosis Trust supporting us is a real boost to our clinical efforts and we are grateful to the Aberdeen CF Patient Group for creating this alliance. With Lynovex, we hope to realise our ambition to improve patients’ lives with an effective, safe, long-term therapy.”
Ed Owen, Chief Executive of the Cystic Fibrosis Trust added:
“Working collaboratively with academics and industry increases our capacity to support transformational research projects to help develop new drugs for people living with cystic fibrosis. We are pleased to be part funding this project and look forward to the results.
“This work forms part of our five year strategy which aims to see the trust engage closely with partners in research and industry, to develop new therapies and treatment, such as Lynovex, to further the quality and length of life of all people with cystic fibrosis.”
Trials will begin in the New Year with results expected at the end of 2014.
AB21 9TR, UK
Tel: +44 (0)1224 711377
9121 Anson Way,
North Carolina 27615, US
Tel: +1 919 578 4216
Fax: +1 919 573 9409